Literature DB >> 26979387

Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.

G M Goodwin1, P M Haddad2, I N Ferrier3, J K Aronson4, Trh Barnes5, A Cipriani6, D R Coghill7, S Fazel6, J R Geddes6, H Grunze8, E A Holmes9, O Howes10, S Hudson11, N Hunt12, I Jones13, I C Macmillan14, H McAllister-Williams3, D R Miklowitz15, R Morriss16, M Munafò17, C Paton18, B J Saharkian19, Kea Saunders6, Jma Sinclair20, D Taylor21, E Vieta22, A H Young23.   

Abstract

The British Association for Psychopharmacology guidelines specify the scope and targets of treatment for bipolar disorder. The third version is based explicitly on the available evidence and presented, like previous Clinical Practice Guidelines, as recommendations to aid clinical decision making for practitioners: it may also serve as a source of information for patients and carers, and assist audit. The recommendations are presented together with a more detailed review of the corresponding evidence. A consensus meeting, involving experts in bipolar disorder and its treatment, reviewed key areas and considered the strength of evidence and clinical implications. The guidelines were drawn up after extensive feedback from these participants. The best evidence from randomized controlled trials and, where available, observational studies employing quasi-experimental designs was used to evaluate treatment options. The strength of recommendations has been described using the GRADE approach. The guidelines cover the diagnosis of bipolar disorder, clinical management, and strategies for the use of medicines in short-term treatment of episodes, relapse prevention and stopping treatment. The use of medication is integrated with a coherent approach to psychoeducation and behaviour change.
© The Author(s) 2016.

Entities:  

Keywords:  Bipolar disorder; antidepressants; antipsychotics; cognitive behaviour therapy; evidence-based guidelines; lithium; mood stabilizers; psychoeducation; treatment

Mesh:

Substances:

Year:  2016        PMID: 26979387      PMCID: PMC4922419          DOI: 10.1177/0269881116636545

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  422 in total

1.  A history of investigation on the mood stabilizing effect of carbamazepine in Japan.

Authors:  T Okuma; A Kishimoto
Journal:  Psychiatry Clin Neurosci       Date:  1998-02       Impact factor: 5.188

Review 2.  Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Committee on Drugs. American Academy of Pediatrics.

Authors: 
Journal:  Pediatrics       Date:  2000-04       Impact factor: 7.124

Review 3.  Diagnostic guidelines for bipolar depression: a probabilistic approach.

Authors:  Philip B Mitchell; Guy M Goodwin; Gordon F Johnson; Robert M A Hirschfeld
Journal:  Bipolar Disord       Date:  2008-02       Impact factor: 6.744

4.  Mood and anxiety spectrum as a means to identify clinically relevant subtypes of bipolar I disorder.

Authors:  Andrea Fagiolini; Ellen Frank; Paola Rucci; Giovanni B Cassano; Scott Turkin; David J Kupfer
Journal:  Bipolar Disord       Date:  2007-08       Impact factor: 6.744

Review 5.  Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.

Authors:  Andrea Cipriani; Keith Reid; Allan H Young; Karine Macritchie; John Geddes
Journal:  Cochrane Database Syst Rev       Date:  2013-10-17

6.  Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial.

Authors:  F Colom; E Vieta; J Sánchez-Moreno; R Palomino-Otiniano; M Reinares; J M Goikolea; A Benabarre; A Martínez-Arán
Journal:  Br J Psychiatry       Date:  2009-03       Impact factor: 9.319

7.  Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study.

Authors:  E Vieta; J R Calabrese; J M Goikolea; S Raines; W Macfadden
Journal:  Bipolar Disord       Date:  2007-06       Impact factor: 6.744

8.  Facilitated Integrated Mood Management for adults with bipolar disorder.

Authors:  David J Miklowitz; Jonathan Price; Emily A Holmes; Jennifer Rendell; Sarah Bell; Katie Budge; Jean Christensen; Joshua Wallace; Judit Simon; Neil M Armstrong; Lily McPeake; Guy M Goodwin; John R Geddes
Journal:  Bipolar Disord       Date:  2012-03       Impact factor: 6.744

9.  A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities.

Authors:  Johanna Michl; Christian Scharinger; Miriam Zauner; Siegfried Kasper; Michael Freissmuth; Harald H Sitte; Gerhard F Ecker; Lukas Pezawas
Journal:  Eur Neuropsychopharmacol       Date:  2014-07-03       Impact factor: 4.600

Review 10.  Balancing benefit and risk of medicines: a systematic review and classification of available methodologies.

Authors:  Shahrul Mt-Isa; Christine E Hallgreen; Nan Wang; Torbjörn Callréus; Georgy Genov; Ian Hirsch; Stephen F Hobbiger; Kimberley S Hockley; Davide Luciani; Lawrence D Phillips; George Quartey; Sinan B Sarac; Isabelle Stoeckert; Ioanna Tzoulaki; Alain Micaleff; Deborah Ashby
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-05-13       Impact factor: 2.890

View more
  151 in total

1.  Lithium monotherapy associated clinical improvement effects on amygdala-ventromedial prefrontal cortex resting state connectivity in bipolar disorder.

Authors:  Murat Altinay; Harish Karne; Amit Anand
Journal:  J Affect Disord       Date:  2017-06-27       Impact factor: 4.839

Review 2.  Medication Adherence in Patients with Bipolar Disorder: A Comprehensive Review.

Authors:  Jennifer B Levin; Anna Krivenko; Molly Howland; Rebecca Schlachet; Martha Sajatovic
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

3.  Treatment of Bipolar Depression with Deep TMS: Results from a Double-Blind, Randomized, Parallel Group, Sham-Controlled Clinical Trial.

Authors:  Diego F Tavares; Martin L Myczkowski; Rodrigo L Alberto; Leandro Valiengo; Rosa M Rios; Pedro Gordon; Bernardo de Sampaio-Junior; Izio Klein; Carlos G Mansur; Marco Antonio Marcolin; Beny Lafer; Ricardo A Moreno; Wagner Gattaz; Zafiris J Daskalakis; André R Brunoni
Journal:  Neuropsychopharmacology       Date:  2017-02-01       Impact factor: 7.853

Review 4.  Treatment of Bipolar Disorder in a Lifetime Perspective: Is Lithium Still the Best Choice?

Authors:  Gabriele Sani; Giulio Perugi; Leonardo Tondo
Journal:  Clin Drug Investig       Date:  2017-08       Impact factor: 2.859

5.  Sleep and Circadian Rhythm Disorder in Bipolar Affective Disorder.

Authors:  Attia Ahmad; Kirstie N Anderson; Stuart Watson
Journal:  Curr Top Behav Neurosci       Date:  2021

6.  Case report of a switch to mania induced by lurasidone.

Authors:  Mark Kanzawa; Olga Hadden
Journal:  Ther Adv Psychopharmacol       Date:  2016-12-02

Review 7.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

8.  Pharmacological Treatment of Bipolar Disorder with Comorbid Alcohol Use Disorder.

Authors:  Andrew Naglich; Bryon Adinoff; E Sherwood Brown
Journal:  CNS Drugs       Date:  2017-08       Impact factor: 5.749

9.  Lithium for acute mania.

Authors:  Rebecca F McKnight; Saïk J G N de La Motte de Broöns de Vauvert; Edward Chesney; Ben H Amit; John Geddes; Andrea Cipriani
Journal:  Cochrane Database Syst Rev       Date:  2019-06-01

Review 10.  Dispensability of Annual Laboratory Follow-Up After More than 2 Years of Valproic Acid Use: A Systematic Review.

Authors:  Rosanne W Meijboom; Koen P Grootens
Journal:  CNS Drugs       Date:  2017-11       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.